Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802370 | 1.00 | MTNR1A (0.48) | MTNR1AMTNR1BSTING1LPAR1CYP3A4 | |
| SCHEMBL19475243 | 0.89 | MTNR1A (0.42) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL22996918 | 0.86 | LPAR1 (0.39) | LPAR1NLRP3 | |
| SCHEMBL22802358 | 0.82 | TSHR (0.39) | LPAR1CYP3A4 | |
| SCHEMBL23692360 | 0.79 | NLRP3 (0.36) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL19508129 | 0.78 | PSEN1 (0.39) | MTNR1AMTNR1B | |
| SCHEMBL25067001 | 0.78 | MTNR1A (0.46) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL30957786 | 0.77 | NLRP3 (0.43) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL22802393 | 0.76 | NLRP3 (0.49) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL30163219 | 0.76 | NLRP3 (0.49) | MTNR1AMTNR1BNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-01-30 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | MTNR1A 828/4885MTNR1B 1306/4885STING1 2168/4885 |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, ABCC5 | MTNR1A 606/4885MTNR1B 946/4885STING1 2046/4885 |
| US-11530200-B2 | Compounds | NLRP3, NOD1, NLRP1 | MTNR1A 321/4885MTNR1B 553/4885STING1 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.